Pleurodesis for malignant pleural effusions: Current controversies and variations in practices

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 4, 2004, Pages 305-310

  West, Sophie D ^a   Davies, Robert J O ^a   Lee, Y C Gary ^a,b,c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Malignant pleural effusions; Pleurodesis; Respiratory failure; Talc

Indexed keywords

BLEOMYCIN; BUPIVACAINE; DOXYCYCLINE; LIDOCAINE; MEPACRINE; SILVER NITRATE; TALC; TETRACYCLINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL EMBOLISM; CLINICAL TRIAL; DRUG COST; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG SAFETY; FEVER; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; MEDICAL PRACTICE; NONHUMAN; PAIN; PLEURA EFFUSION; PLEURA FLUID; PLEURAL FIBROSIS; PLEURISY; PLEURODESIS; PNEUMONIA; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT;

EID: 3042631924     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcp.0000129756.87090.55     Document Type: Review

References (54)

1. Lee YCG, Light RW: Management of malignant pleural effusions. Respirology 2004, in press.
2. Rodriguez-Panadero F: Malignant pleural effusions. In Textbook of Pleural Diseases. Edited by Light RW, Lee YCG. Arnold Press; 2003:297-309.
3. Lee YCG, Davies RJO: Management of pleural effusions in acute medical settings: A practical guide. CPD Journal of Acute Medicine 2004, in press.
4. Lee YCG, Baumann MH, Maskell NA, et al.: Pleurodesis practice for malignant pleural effusions in five English speaking countries: Survey of pulmonologists. Chest 2003, 124:2229-2238.
5. Walker-Renard PB, Vaughan LM, Sahn SA: Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994, 120:56-64.
6. Lee YCG, Rodriguez RM, Lane KB, Light RW: Pleurodesis for recurrent pleural effusions in the new millennium. Recent Advances and Research Updates 2001, 2:81-89.
7. Stiksa G, Korsgaard R, Simonsson BG: Treatment of recurrent pleural effusion by pleurodesis with quinacrine. Comparison between instillation by repeated thoracenteses and by tube drainage. Scand J Respir Dis 1979, 60:197-205.
8. Urata A, Nishimura M, Ota K: Randomized controlled study of OK-432 in the treatment of cancerous pleurisy. Gan To Kagaku Ryoho 1983, 10:1497-1503.
9. Vargas FS, Carmo AO, Teixeira LR: A new look at old agents for pleurodesis. Nitrogen mustard, sodium hydroxide, and silver nitrate. Curr Opin Pulm Med 2000, 6:281-286.
10. Diacon AH, Wyser C, Bollinger CT, et al.: Prospective randomized comparison of thoracoscopic talc poudrage under local anaethesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 2000, 162:1445-1449.
11. Hartman DL, Gaither JM, Kesler KA, et al.: Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. Cardiovasc Surg 1993, 105:743-748.
12. Ong KC, Indumathi V, Raghuram J, Ong YY: A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant effusions. Respirology 2000, 5:99-103.
13. Hamed H, Fentiman IS, Chaudary MA, Rubens RD: Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg 1989, 76:1266-1267.
14. Fentiman IS, Rubens RD, Hayward JL: A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Eur J Cancer Oncol 1986, 22:1079-1081.
15. Shaw P, Agarwal R: Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004:CD002916.
16. Lee YCG, Lane KB: The many faces of transforming growth factor beta in pleural diseases. Curr Opin Pulm Med 2001, 7:173-179.
17. Antony VB, Rothfuss KJ, Godbey SW, et al.: Mechanism of tetracycline -hydrochloride-induced pleurodesis. Tetracycline-hydrochloride stimulated mesothelial cells produce a growth-factor like activity for fibroblasts. Am Rev Respir Dis 1992, 146:1009-1013.
18. Baumann MH, Heinrich K, Sahn SA, Strange C: Pleural macrophages differentially alter mesothelial growth and collagen production. Inflammation 1993, 17:1-12.
19. Lee YCG, Lane KB, Zoia O, et al.: Transforming growth factor-beta induces collagen synthesis without inducing IL-8 production in mesothelial cells. Eur Respir J 2003, 22:197-202.
20. Lee YCG, Lane KB: Cytokines in pleural diseases. In Textbook of Pleural Diseases. Edited by Light RW, Lee YCG. Arnold Press; 2003:63-89.
21. Light RW: Talc should not be used for pleurodesis. Am J Respir Crit Care Med 2000, 162:2024-2026.
22. Light RW: Talc for pleurodesis? Chest 2002, 122:1506-1508.
23. Sahn SA: Talc should be used for pleurodesis. Am J Respir Crit Care Med 2000, 162:2023-2024.
24. Werebe EC, Pazetti R, Milanez de Campos JR, et al.: Systemic distribution of talc after intrapleural administration in rats. Chest 1999, 115:190-193.
25. Montes JF, Ferrer J, Villarino MA, et al.: Influence of talc dose on extrapleural talc dissemination after talc pleurodesis. Am J Respir Crit Care Med 2003, 168:348-355.
26. Campos JR, Werebe EC, Vargas FS, et al.: Respiratory failure due to insufflated talc. Lancet 1997, 349:251-252.
27. Rehse DH, Aye RW, Florence MG : Respiratory failure following talc pleurodesis. Am J Surg 1999, 177:437-440.
28. Cardillo G, Facciolo F, Carbone L, et al.: Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg 2002, 21:302-306.
29. Brant A, Eaton T: Serious complications with talc slurry pleurodesis. Respirology 2001, 6:181-185.
30. de Campos JR, Vargas FS, Werebe E, et al.: Thoracoscopy talc poudrage: a 15-year experience. Chest 2001, 119:801-806.
31. Bondoc AY, Bach PB, Sklarin NT, Vander Els NJ: Arterial desaturation syndrome following pleurodesis with talc slurry: incidence, clinical features and outcome, Cancer Invest 2003, 21:848-854.
32. Ferrer J, Montes JF, Villarino MA, et al.: Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002, 122:1018-1027.
33. Maskell NA, Lee YCG, Gleeson FV, et al.: The influence of talc particle size on lung and systemic inflammation after pleurodesis for malignant pleural effusion: randomised trials of talc with a mean diameter <15 μm, talc with a mean diameter >25 μm, and tetracycline. Am J Respir Crit Care Med 2004, in press.
34. Ferrer J, Villarino MA, Tura JM, et al.: Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001, 119:1901-1905.
35. Ferrer J, Valero JG, Castillo JM: Pleural reaction to mineral dust. In Textbook of Pleural Diseases. Edited by Light RW, Lee YCG. Arnold Press; 2003:109-119.
36. Maskell NA, Lee YCG, Gleeson FV, et al.: Prospective randomized trials comparing the influence of talc of different particle sizes and tetracycline on lung and systemic inflammation after pleurodesis. Am J Respir Crit Care Med 2004, in press.
37. Yim AP, Chan AT, Lee TW, et al.: Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996, 62:1655-1658.
38. Loddenkemper R: Medical thoracoscopy. In Textbook of Pleural Diseases. Edited by Light RW, Lee YCG. Arnold Press; 2003:498-512.
39. Rodriguez-Panadero F, Antony VB: Pleurodesis: state of the art. Eur Respir J 1997, 10:1648-1654.
40. Loddenkemper R: Are prognostic factors helpful in determining the indication for pleurodesis in malignant pleural effusions? Respiration 1998, 65:106-107.
41. Seaton KG, Patz EFJ, Goodman PC: Palliative treatment of malignant pleural effusions: value of small-bore catheter thoracostomy and doxycycline sclerotherapy. AJR 1995, 164:589-591.
42. Marom EM, Patz EFJ, Erasmus JJ, et al.: Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. Radiology 1999, 210:277-281.
43. Morrison MC, Mueller PR, Lee MJ, et al.: Sclerotherapy of malignant pleural effusion through sonographically placed small-bore catheters. AJR 1992, 158:41-43.
44. Clementsen P, Evalid T, Grade G, et al.: Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study. Respir Med 1998, 92:593-596.
45. Parker LA, Charnock GC, Delany DJ: Small bore catheter drainage and sclerotherapy for malignant pleural effusions. Cancer 1989, 64:1218-1221.
46. Villanueva AG, Gray AWJ, Shahian DM, et al.: Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994, 49:23-25.
47. Antunes G, Neville E, Duffy J, Ali N: Management of malignant pleural effusions. Thorax 2003, 58(Suppl 2):ii29-ii38.
48. Antony VB, Loddenkemper R, Astoul P, et al.: Management of malignant pleural effusions. Eur Respir J 2001, 18:402-419.
49. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000, 162:1987-2001.
50. Mager HJ, Maesen B, Verzijbergen F, Schramel F: Distribution of talc suspension during treatment of malignant pleural effusions with talc pleurodesis. Lung Cancer 2002, 36:77-81.
51. Dryzer SR, Allen ML, Strange C, Sahn SA: A comparison of rotation and non-rotation in tetracycline pleurodesis. Chest 1993, 104:1763-1766.
52. Lorch DG, Gordon L, Wooten S, et al.: Effect of patient positioning on distribution of tetracycline in the pleural space during pleurodesis. Chest 1988, 93:527-529.
53. Grove CS, Lee YCG: Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002, 8:294-301.
54. Lee YCG, Light RW: Future directions. In Textbook of Pleural Diseases. Edited by Light RW, Lee YCG. Arnold Press; 2003:536-541.